Covering the base-pairs in iodothyronine deiodinase-1 biology: Holes remain in the lineup

Thyroid

Volumn 19, Issue 10, 2009, Pages 1027-1029

  Gereben, Balázs ^a   Bianco, Antonio C ^b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 IODOTHYRONINE DEIODINASE; IODOTHYRONINE DEIODINASE 1; MESSENGER RNA; RNA; THYROID EXTRACT; UNCLASSIFIED DRUG;

CLEAR CELL CARCINOMA; CODON; EDITORIAL; EXON; HUMAN; INTRON; KIDNEY CANCER; KIDNEY TUMOR; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING; SPLICEOSOME; TUMOR GROWTH;

BASE PAIRING; HUMANS; IODIDE PEROXIDASE; MOLECULAR WEIGHT; RNA, MESSENGER; THYROID GLAND; THYROID NEOPLASMS;

EID: 70350662521     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.1593     Document Type: Editorial

References (28)

1. Bianco AC, Kim BW 2006 Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 116: 2571-2579.
2. Chopra IJ 1977 A study of extrathyroidal conversion of thyroxine (T4) to 3,30,5-triiodothyronine (T3) in vitro. Endocrinology 101:453-463.
3. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ 2003 Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 88:2880-2888.
4. Cooper-Kazaz R, van der Deure WM, Medici M, Visser TJ, Alkelai A, Glaser B, Peeters RP, Lerer B 2009 Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord 116:113-116.
5. Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, St Germain DL, Galton VA 2006 Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology 147:580-589.
6. Piekielko-Witkowska A, Master A, Wojcicka A, Boguslawska J, Brozda I, Tanski Z, Nauman A 2009 Disturbed expression of type 1 iodothyronine deiodinase splice variants in human renal cancer. Thyroid 19:1105-1113.
7. Black DL 2003 Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291-336.
8. House AE, Lynch KW 2008 Regulation of alternative splicing: more than just the ABCs. J Biol Chem 283:1217-1221.
9. DiFeo A, Martignetti JA, Narla G 2009 The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 12:1-7.
10. van Alphen RJ, Wiemer EA, Burger H, Eskens FA 2009 The spliceosome as target for anticancer treatment. Br J Cancer 100:228-232.
11. Gereben B, Kollar A, Harney JW, Larsen PR 2002 The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol 16: 1667-1679.
12. Bartha T, Kim SW, Salvatore D, Gereben B, Tu HM, Harney JW, Rudas P, Larsen PR 2000 Characterization of the 50- flanking and 50-untranslated regions of the cyclic adenosine 30,50-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology 141:229-237.
13. Toyoda N, Kleinhaus N, Larsen PR 1996 The structure of the coding and 50-flanking region of the type 1 iodothyronine deiodinase (DIO1) gene is normal in a patient with suspected congenital DIO1 deficiency. J Clin Endocrinol Metab 81:2121-2124.
14. Jakobs TC, Koehler MR, Schmutzler C, Glaser F, Schmid M, Kohrle J 1997 Structure of the human type I iodothyronine 50-deiodinase gene and localization to chromosome 1p32- p33. Genomics 42:361-363.
15. Pachucki J, Ambroziak M, Tanski Z, Luczak J, Nauman J, Nauman A 2001 Type I 50-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 24:253-261.
16. Zhou M, Rubin MA 2001 Molecular markers for renal cell carcinoma: impact on diagnosis and treatment. Semin Urol Oncol 19:80-87.
17. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS 2007 Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol 9:47-56.
18. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS 2009 Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 18: 894-900.
19. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD 2003 Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162: 925-932.
20. Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC, Kim BW 2009 Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology 150:1976-1983.
21. Visser WE, Heemstra KA, Swagemakers SM, Ozgur Z, Corssmit EP, Burggraaf J, van Ijcken WF, van der Spek PJ, Smit JW, Visser TJ 2009 Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts. J Clin Endocrinol Metab 94:3487-3496.
22. da-Silva WS, Harney JW, Kim BW, Li J, Bianco SD, Crescenzi A, Christoffolete MA, Huang SA, Bianco AC 2007 The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes 56: 767-776.
23. Curcio C, Baqui MM, Salvatore D, Rihn BH, Mohr S, Harney JW, Larsen PR, Bianco AC 2001 The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem 276:30183-30187.
24. Huang SA 2005 Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid 15:875-881.
25. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A, Bianco AC 2008 Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 29:898-938.
26. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeold A, Capelo LP, Curcio-Morelli C, Ribeiro R, Harney JW, Tabin CJ, Bianco AC 2005 The Hedgehoginducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol 7:698-705.
27. Ruiz i Altaba A, Sánchez P, Dahmane N 2002 Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2:361-372.
28. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D, Zavacki AM, Fenzi G, Grachtchouk M, Hutchin M, Dlugosz AA, Bianco AC, Missero C, Larsen PR, Salvatore D 2007 Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci USA 104:14466-14471.